Ombitasvir, paritaprevir, ritonavir and dasabuvir and Wakix Tablets
Determining the interaction of Ombitasvir, paritaprevir, ritonavir and dasabuvir and Wakix Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Pitolisant is a borderline/weak inducer of CYP450 3A4. When studied with midazolam, a probe substrate for CYP450 3A4, pitolisant was found to reduce midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) by less than 25%. MANAGEMENT: Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates. Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary. It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA.
Professional:MONITOR: Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Pitolisant is a borderline/weak inducer of CYP450 3A4. When studied with midazolam, a probe substrate for CYP450 3A4, pitolisant was found to reduce midazolam peak plasma concentration (Cmax) and systemic exposure (AUC) by less than 25%.
MANAGEMENT: Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates. Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary. It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA.
Generic Name: dasabuvir / ombitasvir / paritaprevir / ritonavir
Brand name: Viekira XR, Viekira Pak
Synonyms: Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets, and Dasabuvir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Wal-Fex
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Wal-finate
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Wal-itin
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Wal-Zyr D
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Walgreens Ibuprofen Junior Strength
- Ombitasvir, paritaprevir, ritonavir and dasabuvir-Warfarin
- Wakix Tablets-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Extended-Release Tablets
- Wakix Tablets-Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Tablets
- Wakix Tablets-Omeclamox-Pak
- Wakix Tablets-Omega-3 Fatty Acid Capsules
- Wakix Tablets-Omega-3 Fatty Acids
- Wakix Tablets-Omega-3 polyunsaturated fatty acids